Patents by Inventor Kevin J. French

Kevin J. French has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine kinase inhibitors
    Patent number: 8557800
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: October 15, 2013
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang
  • Methods for the treatment and prevention of inflammatory diseases
    Patent number: 8324237
    Abstract: The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: December 4, 2012
    Inventors: Charles D. Smith, Kevin J. French, Lynn W. Maines
  • Sphingosine Kinase Inhibitors
    Publication number: 20120095004
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Application
    Filed: October 19, 2011
    Publication date: April 19, 2012
    Applicant: APOGEE BIOTECHNOLOGY CORPORATION
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang
  • Sphingosine kinase inhibitors
    Patent number: 8063248
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: November 22, 2011
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang
  • Sphingosine Kinase Inhibitors and Methods of Their Use
    Publication number: 20100137315
    Abstract: The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Application
    Filed: November 30, 2009
    Publication date: June 3, 2010
    Applicant: APOGEE BIOTECHNOLOGY CORPORATION
    Inventors: Charles D. Smith, Kevin J. French, Zuping Xia
  • Sphingosine Kinase Inhibitors
    Publication number: 20080167352
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Application
    Filed: December 23, 2007
    Publication date: July 10, 2008
    Applicant: APOGEE BIOTECHNOLOGY CORPORATION
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang
  • Sphingosine kinase inhibitors
    Patent number: 7338961
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: March 4, 2008
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang
  • Sphingosine kinase inhibitors
    Patent number: 7220764
    Abstract: The invention relates to compositions and methods for inhibiting sphingosine kinase and for treating hyperproliferative disease.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: May 22, 2007
    Assignee: The Pennsylvania State University Research Foundation
    Inventors: Charles D. Smith, Kevin J. French, Jong K. Yun
  • Sphingosine kinase inhibitors
    Publication number: 20040034075
    Abstract: The invention relates to compounds, compositions and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy.
    Type: Application
    Filed: June 17, 2003
    Publication date: February 19, 2004
    Applicant: The Pennsylvania State University Research Foundation
    Inventors: Charles D. Smith, Kevin J. French, Jong K. Yun
  • N-myristoyltransferase inhibitor compositions and methods of use
    Publication number: 20040014764
    Abstract: The invention is a pharmaceutical composition mainly for the treatment of a hyperproliferative disease, such as cancer, atherosclerosis, restenosis or psoriasis, or viral infection. The active ingredient of the composition is a compound that inhibits the activity of human N-myristoyltransferase (NMT). The NMT inhibitors are small molecule non-lipid compounds containing a cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine (COPP) or methyl-octahydro-pyrrolo[1,2-a]pyrazine (MOPP) group.
    Type: Application
    Filed: March 26, 2003
    Publication date: January 22, 2004
    Inventors: Charles D. Smith, Kevin J. French
  • Sphingosine kinase inhibitors
    Patent number: RE49811
    Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: January 23, 2024
    Assignee: Apogee Biotechnology Corporation
    Inventors: Charles D. Smith, Kevin J. French, Yan Zhuang